Eli Lilly and Company (NYSE:LLY) Shares Purchased by Global Retirement Partners LLC

Global Retirement Partners LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,058 shares of the company's stock after purchasing an additional 1,075 shares during the quarter. Global Retirement Partners LLC's holdings in Eli Lilly and Company were worth $15,484,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. AMF Tjanstepension AB increased its holdings in shares of Eli Lilly and Company by 113.7% in the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company's stock valued at $293,964,000 after purchasing an additional 176,552 shares during the last quarter. Values Added Financial LLC grew its holdings in Eli Lilly and Company by 4.9% in the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company's stock valued at $324,000 after buying an additional 17 shares in the last quarter. Kessler Investment Group LLC increased its stake in shares of Eli Lilly and Company by 129.7% in the 3rd quarter. Kessler Investment Group LLC now owns 5,687 shares of the company's stock worth $5,038,000 after acquiring an additional 3,211 shares during the last quarter. RFP Financial Group LLC raised its holdings in shares of Eli Lilly and Company by 89.4% during the 3rd quarter. RFP Financial Group LLC now owns 2,580 shares of the company's stock worth $2,285,000 after acquiring an additional 1,218 shares during the period. Finally, Graybill Wealth Management LTD. raised its holdings in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Graybill Wealth Management LTD. now owns 895 shares of the company's stock worth $793,000 after acquiring an additional 45 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $3.50 during midday trading on Friday, reaching $876.62. 2,775,916 shares of the stock were exchanged, compared to its average volume of 3,728,728. The company has a market capitalization of $832.19 billion, a price-to-earnings ratio of 74.82, a PEG ratio of 1.39 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The business's 50-day moving average price is $799.63 and its 200 day moving average price is $846.07.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has approved a share buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to buy up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.68%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 51.24%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on LLY shares. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Wolfe Research assumed coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 price objective for the company. Bank of America restated a "buy" rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Barclays decreased their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating for the company in a research report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $997.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.